Novel Plasmodium falciparum metabolic network reconstruction identifies shifts associated with clinical antimalarial resistance

BMC Genomics

Volumn 18, Issue 1, 2017, Pages

  Carey, Maureen A ^a   Papin, Jason A ^b   Guler, Jennifer L ^a,c  

^a UNIVERSITY OF VIRGINIA   (United States)

^b University of Virginia   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Artemisinin resistance; Flux balance analysis; Malaria; Metabolism; Network reconstruction; Plasmodium falciparum

Indexed keywords

ARTEMISININ; FOLIC ACID; POLYAMINE; TRANSCRIPTOME; ANTIMALARIAL AGENT;

ANTIMALARIAL DRUG RESISTANCE; ARTICLE; BIOMASS; BIOSYNTHESIS; ENZYME INHIBITION; GENE INACTIVATION; METABOLOMICS; MICROBIAL METABOLISM; PLASMODIUM FALCIPARUM; SIMULATION; SYSTEMS BIOLOGY; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENETICS; METABOLIC FLUX ANALYSIS; METABOLISM;

ANTIMALARIALS; BIOMASS; DRUG RESISTANCE; GENE EXPRESSION PROFILING; METABOLIC FLUX ANALYSIS; METABOLIC NETWORKS AND PATHWAYS; METABOLOMICS; PLASMODIUM FALCIPARUM; SYSTEMS BIOLOGY;

EID: 85025100842     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/s12864-017-3905-1     Document Type: Article

References (156)

1. Schwartz, E. and T. Lachish, Artemisinin-based combination therapy (ACT) versus atovaquone-proguanil: do not choose between but, rather, combine them. Evidence Based Medicine, 2016. 21(2): p. 64-64.
2. Olliaro PL, Taylor WR. Developing artemisinin based drug combinations for the treatment of drug resistant falciparum malaria: a review. J Postgrad Med. 2004;50(1):40.
3. Eastman RT, Fidock DA. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat Rev Microbiol. 2009;7(12):864-74.
4. Chakraborty A. Emerging drug resistance in plasmodium falciparum: a review of well-characterized drug targets for novel antimalarial chemotherapy. Asian Pac J of Tro Dis. 2016;6(7):581-8.
5. Cowman AF, et al. Malaria: biology and disease. Cell. 2016;167(3):610-24.
6. Plowe CV, et al. World antimalarial resistance network (WARN) III: molecular markers for drug resistant malaria. Malar J. 2007;6(1):1-10.
7. Sidhu AB, Verdier-Pinard D, Fidock DA. Chloroquine resistance in plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science. 2002;298
8. Guler JL, et al. Atovaquone tolerance in plasmodium falciparum parasites selected for high-level resistance to a dihydroorotate dehydrogenase inhibitor. Antimicrob Agents Chemother. 2015;59(1):686-9.
9. Herman JD, et al. A genomic and evolutionary approach reveals non-genetic drug resistance in malaria. Genome Biol. 2014;15(11):511.
10. Gabryszewski, S.J., et al., Evolution of Fitness Cost-Neutral Mutant PfCRT Conferring P. falciparum 4-Aminoquinoline Drug Resistance Is Accompanied by Altered Parasite Metabolism and Digestive Vacuole Physiology. PLOS Pathog, 2016. 12(11): p. e1005976.
11. Meylan S, et al. Carbon sources tune antibiotic susceptibility in Pseudomonas Aeruginosa via tricarboxylic acid cycle control. Cell Chem Biol. 2017; 24:195-206.
12. El-Halfawy OM, Valvano MA. Non-genetic mechanisms communicating antibiotic resistance: rethinking strategies for antimicrobial drug design. Expert Opin Drug Discov. 2012;7(10):923-33.
13. Ashley EA, et al. Spread of artemisinin resistance in plasmodium falciparum malaria. N Engl J Med. 2014;371(5):411-23.
14. Miotto O, et al. Genetic architecture of artemisinin-resistant plasmodium falciparum. Nat Genet. 2015;47(3):226-34.
15. Straimer J, et al. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science. 2015;347(6220):428-31.
16. Ariey F, et al. A molecular marker of artemisinin-resistant plasmodium falciparum malaria. Nature. 2014;505(7481):50-5.
17. Brown TS, et al. Plasmodium falciparum field isolates from areas of repeated emergence of drug resistant malaria show no evidence of hypermutator phenotype. Infection, Genetics and Evolution: J Mol Epidemiol Evol Genet Infect Dis. 2015;30:318-22.
18. Cheng Q, Kyle DE, Gatton ML. Artemisinin resistance in Plasmodium falciparum: A process linked to dormancy? International Journal for parasitology. Drugs and Drug Resist. 2012;2:249-55.
19. Codd A, et al. Artemisinin-induced parasite dormancy: a plausible mechanism for treatment failure. Malar J. 2011;10
20. Straimer J, et al. Drug resistance. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Sci. 2015;347(6220):428-31.
21. Mbengue A, et al. A molecular mechanism of artemisinin resistance in plasmodium falciparum malaria. Nat. 2015;520(7549):683-7.
22. Ying-Zi Y, Little B, Meshnick SR. Alkylation of proteins by artemisinin: effects of heme, pH, and drug structure. Biochem Pharmacol. 1994;48(3):569-73.
23. Dalal S, Klemba M. Amino acid efflux by asexual blood-stage plasmodium falciparum and its utility in interrogating the kinetics of hemoglobin endocytosis and catabolism in vivo. Mol Biochem Parasitol. 2015;201(2):116-22.
24. Klonis N, et al. Artemisinin activity against plasmodium falciparum requires hemoglobin uptake and digestion. Proc Natl Acad Sci U S A. 2011;108(28):11405-10.
25. Wang J, et al. Artemisinin Directly Targets Malarial Mitochondria through Its Specific Mitochondrial Activation. PLoS One. 2010;5(3):e9582.
26. Chen N, et al. Fatty acid synthesis and pyruvate metabolism pathways remain active in Dihydroartemisinin-induced dormant ring stages of plasmodium falciparum. Antimicrob Agents Chemother. 2014;58(8):4773-81.
27. Vega-Rodríguez J, et al. Implications of glutathione levels in the plasmodium berghei response to chloroquine and artemisinin. PLoS One. 2015;10(5):e0128212.
28. Cobbold SA, et al. Metabolic dysregulation induced in plasmodium falciparum by Dihydroartemisinin and other front-line antimalarial drugs. J Infect Dis. 2016;213(2):276-86.
29. Peatey CL, et al. Mitochondrial membrane potential in a small subset of artemisinin-induced dormant plasmodium falciparum parasites in vitro. J Infect Dis. 2015;212(3):426-34.
30. Meshnick SR. Artemisinin: mechanisms of action, resistance and toxicity. Int J Parasitol. 2002;32(13):1655-60.
31. Eckstein-Ludwig U, et al. Artemisinins target the SERCA of plasmodium falciparum. Nature. 2003;424(6951):957-61.
32. Golenser J, et al. Current perspectives on the mechanism of action of artemisinins. Int J Parasitol. 2006;36(14):1427-41.
33. Efferth T, Oesch F. Oxidative stress response of tumor cells: microarray-based comparison between artemisinins and anthracyclines. Biochem Pharmacol. 2004;68(1):3-10.
34. Antoine T, et al. Rapid kill of malaria parasites by artemisinin and semi-synthetic endoperoxides involves ROS-dependent depolarization of the membrane potential. J Antimicrob Chemother. 2014;69(4):1005-16.
35. Sun C, et al. Two distinct and competitive pathways confer the cellcidal actions of artemisinins. Microbial Cell. 2015;2(1):14-25.
36. Li, W., et al., Yeast model uncovers dual roles of mitochondria in the action of artemisinin. PLoS Genet, 2005. 1(3): p. e36.
37. Kamau E, et al. K13-propeller polymorphisms in plasmodium falciparum parasites from sub-Saharan Africa. J Infect Dis. 2015;211(8):1352-5.
38. Isozumi R, et al. Novel mutations in K13 propeller Gene of artemisinin-resistant plasmodium falciparum. Emerg Infect Dis. 2015;21(3):490-2.
39. Klonis N, et al. Altered temporal response of malaria parasites determines differential sensitivity to artemisinin. Proc Natl Acad Sci U S A. 2013;110(13):5157-62.
40. Mok S, et al. Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription. BMC Genomics. 2011:12(1).
41. Teuscher F, et al. Artemisinin-induced dormancy in plasmodium falciparum: duration, recovery rates, and implications in treatment failure. J Infect Dis. 2010;202(9):1362-8.
42. Witkowski B, et al. Increased tolerance to artemisinin in plasmodium falciparum is mediated by a quiescence mechanism. Antimicrob Agents Chemother. 2010;54(5):1872-7.
43. Collaborativea TPGD, PlasmoDB: An integrative database of the Plasmodium falciparum genome. Tools for accessing and analyzing finished and unfinished sequence data. Nucleic Acids Res. 2001;29(1):66-9.
44. Fidock DA, et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell. 2000:6.
45. Peterson DS, Walliker D, Wellems TE. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci U S A. 1988;85(23):9114-9118.
46. Siregar JE, et al. Direct evidence for the atovaquone action on the plasmodium cytochrome bc1 complex. Parasitol Int. 2015;64(3):295-300.
47. Phillips MA, Rathod PK. Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy. Infect Disord Drug Targets. 2010;10(3):226-39.
48. Fuhrer T, et al. Genomewide landscape of gene-metabolome associations in Escherichia coli. Mol Syst Biol. 2017;13(1):907.
49. Mok S, et al. Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. Science. 2015;347(6220):431-5.
50. Plata G, et al. Reconstruction and flux-balance analysis of the plasmodium falciparum metabolic network. Mol Syst Biol. 2010;6
51. Painter HJ, et al. Specific role of mitochondrial electron transport in blood-stage plasmodium falciparum. Nature. 2007;446(7131):88-91.
52. Langer RC, Vinetz JM. Plasmodium ookinete-secreted chitinase and parasite penetration of the mosquito peritrophic matrix. Trends Parasitol. 2001;17(6):269-72.
53. Thiele I, Palsson BO. A protocol for generating a high-quality genome-scale metabolic reconstruction. Nat Protocols. 2010;5(1):93-121.
54. Sturm A, et al. Mitochondrial ATP synthase is dispensable in blood-stage plasmodium berghei rodent malaria but essential in the mosquito phase. Proc Natl Acad Sci. 2015;112(33):10216-23.
55. Ginsburg H. Abundant proton pumping in plasmodium, but why? Trends Parasitol. 2002;18(11):483-6.
56. Gulati S, et al. Profiling the essential nature of lipid metabolism in asexual blood and gametocyte stages of plasmodium falciparum. Cell Host Microbe. 2015;18(3):371-81.
57. Olszewski KL, et al. Host-parasite interactions revealed by plasmodium falciparum metabolomics. Cell Host Microbe. 2009;5(2):191-9.
58. Sana TR, et al. Global Mass Spectrometry Based Metabolomics Profiling of Erythrocytes Infected with Plasmodium falciparum. PLoS One. 2013;8(4):e60840.
59. Biddau M, Müller S. Carbon Metabolism of Plasmodium falciparum. Compr Anal Parasite Biol: Metab to Drug Discov. 2016:371.
60. Ke H, et al. Genetic investigation of tricarboxylic acid metabolism during the plasmodium falciparum life cycle. Cell Rep. 2015;11(1):164-74.
61. MacRae JI, et al. Mitochondrial metabolism of sexual and asexual blood stages of the malaria parasite plasmodium falciparum. BMC Biol. 2013;11(1):67.
62. Yeh I. Computational analysis of plasmodium falciparum metabolism: organizing genomic information to facilitate drug discovery. Genome Res. 2004;14(5):917-24.
63. Liu J, et al. Plasmodium falciparum ensures its amino acid supply with multiple acquisition pathways and redundant proteolytic enzyme systems. Proc Natl Acad Sci U S A. 2006;103(23):8840-5.
64. Krugliak M, Zhang J, Ginsburg H. Intraerythrocytic plasmodium falciparum utilizes only a fraction of the amino acids derived from the digestion of host cell cytosol for the biosynthesis of its proteins. Mol Biochem Parasitol. 2002;119(2):249-56.
65. Asahi H, et al. Hypoxanthine: a low molecular weight factor essential for growth of erythrocytic plasmodium falciparum in a serum-free medium. Parasitol. 1996;113(01):19-23.
66. Geary TG, et al. Nutritional requirements of plasmodium falciparum in culture. III. Further observations on essential nutrients and antimetabolites. The J Protozool. 1985;32(4):608-13.
67. Miller LH, et al. The pathogenic basis of malaria. Nature. 2002;415(6872):673-9.
68. Geary TG, Divo AA, Jensen JB. Nutritional requirements of plasmodium falciparum in culture. II. Effects of antimetabolites in a semi defined medium. The J Protozool. 1985;32(1):65-9.
69. Jensen PA, Papin JA. Functional integration of a metabolic network model and expression data without arbitrary thresholding. Bioinform. 2011;27(4):541-7.
70. Fang X, Reifman J, Wallqvist A. Modeling metabolism and stage-specific growth of plasmodium falciparum HB3 during the intraerythrocytic developmental cycle. Mol BioSyst. 2014;10(10):2526-37.
71. Chiappino-Pepe A, et al. Bioenergetics-based modeling of plasmodium falciparum metabolism reveals its essential genes, nutritional requirements, and thermodynamic bottlenecks. PLoS Comput Biol. 2017;13(3):e1005397.
72. Wallqvist A, et al. Metabolic host responses to malarial infection during the intraerythrocytic developmental cycle. BMC Syst Biol. 2016;10(1):58.
73. Tymoshenko S, et al. Functional genomics of plasmodium falciparum using metabolic modelling and analysis. Briefings in Functional Genomics. 2013;12(4):316-27.
74. Bazzani S, Hoppe A, Holzhütter H-G. Network-based assessment of the selectivity of metabolic drug targets in Plasmodium falciparum with respect to human liver metabolism. BMC Syst Biol. 2012:6(1).
75. Aurrecoechea, C., et al., EuPathDB: the eukaryotic pathogen genomics database resource. Nucleic Acids Res, 2017: 45:D581-D591.
76. Gardner MJ, et al. Genome sequence of the human malaria parasite plasmodium falciparum. Nat. 2002;419(6906):498-511.
77. Gajria B, et al. ToxoDB: an integrated Toxoplasma gondii database resource. Nucleic Acids Res. 2008;36(Database issue):D553-6.
78. Xia D, et al. The proteome of Toxoplasma gondii: integration with the genome provides novel insights into gene expression and annotation. Genome Biol. 2008;9(7):R116.
79. Tymoshenko S, et al. Metabolic needs and capabilities of Toxoplasma gondii through combined Computational and experimental analysis. PLoS Comput Biol. 2015;11(5):e1004261.
80. Ivens AC, et al. The genome of the Kinetoplastid parasite, Leishmania major. Sci. 2005;309(5733):436.
81. Chavali AK, et al. Systems analysis of metabolism in the pathogenic trypanosomatid Leishmania major. Mol Syst Biol. 2008;4(1):177.
82. Orth, J.D., et al., A comprehensive genome-scale reconstruction of Escherichia coli metabolism-2011. Mol Syst Biol, 2011. 7: p. 535-535.
83. Heavner BD, Price ND. Comparative analysis of yeast metabolic network models highlights progress, opportunities for metabolic reconstruction. PLoS Comput Biol. 2015;11(11):e1004530.
84. McConville M. Open questions: microbes, metabolism and host-pathogen interactions. BMC Biol. 2014;12(1):18.
85. Wellems TE, Fairhurst RM. An evolving picture of the interactions between malaria parasites and their host erythrocytes. Cell Res. 2012;22(3):453-6.
86. Imlay L, Odom AR. Isoprenoid metabolism in apicomplexan parasites. Current Clinical Microbiology Reports. 2014;1(3-4):37-50.
87. Mazumdar J, Striepen B. Make it or take it: fatty acid metabolism of apicomplexan parasites. Eukaryot Cell. 2007;6(10):1727-35.
88. Lanzer M, et al. Maurer's clefts: a novel multi-functional organelle in the cytoplasm of plasmodium falciparum-infected erythrocytes. Int J Parasitol. 2006;36(1):23-36.
89. Bannister LH, et al. A brief illustrated guide to the ultrastructure of plasmodium falciparum asexual blood stages. Parasitol Today. 2000;16(10):427-33.
90. Baumeister S, et al. Evidence for the involvement of plasmodium falciparum proteins in the formation of new permeability pathways in the erythrocyte membrane. Mol Microbiol. 2006;60(2):493-504.
91. Ginsburg H, et al. New permeability pathways induced in membranes of plasmodium falciparum infected erythrocytes. Mol Biochem Parasitol. 1983;8(2):177-90.
92. Staines HM, et al. Solute transport via the new permeability pathways in plasmodium falciparum-infected human red blood cells is not consistent with a simple single-channel model. Blood. 2006;108(9):3187-94.
93. Divo AA, et al. Nutritional requirements of plasmodium falciparum in culture. I. Exogenously supplied dialyzable components necessary for continuous growth. J Protozool. 1985;32(1):59-64.
94. Phaiphinit S, et al. In silico multiple-targets identification for heme detoxification in the human malaria parasite plasmodium falciparum. Infect Genet Evol. 2016;37:237-44.
95. Ghorbal M, et al. Genome editing in the human malaria parasite plasmodium falciparum using the CRISPR-Cas9 system. Nat Biotech. 2014;32(8):819-21.
96. Lee MCS, Fidock DA. CRISPR-mediated genome editing of plasmodium falciparum malaria parasites. Genome Med. 2014;6(8):63.
97. Wagner JC, et al. Efficient CRISPR-Cas9-mediated genome editing in plasmodium falciparum. Nat Meth. 2014;11(9):915-8.
98. Lu J, et al. A redesigned CRISPR/Cas9 system for marker-free genome editing in plasmodium falciparum. Parasit Vectors. 2016;9(1):1.
99. Ramya TNC, et al. Inhibitors of nonhousekeeping functions of the apicoplast defy delayed death in plasmodium falciparum. Antimicrob Agents Chemother. 2007;51(1):307-16.
100. Ke H, et al. The heme biosynthesis pathway is essential for plasmodium falciparum development in mosquito stage but not in blood stages. J Biol Chem. 2014;289(50):34827-37.
101. Nagaraj VA, et al. Malaria parasite-synthesized Heme is essential in the mosquito and liver stages and complements host Heme in the blood stages of infection. PLoS Pathog. 2013;9(8):e1003522.
102. Ho M-C, et al. Structural and metabolic specificity of methylthiocoformycin for malarial adenosine deaminases. Biochemistry. 2009;48(40):9618-26.
103. Zhou Y, Li W, Xiao Y. Profiling of multiple targets of artemisinin activated by hemin in cancer cell proteome. ACS Chem Biol. 2016;11(4):882-8.
104. Ismail HM, et al. Artemisinin activity-based probes identify multiple molecular targets within the asexual stage of the malaria parasites plasmodium falciparum 3D7. Proc Natl Acad Sci. 2016;113(8):2080-5.
105. Prieto JH, et al. Large-Scale Differential Proteome Analysis in Plasmodium falciparum under Drug Treatment. PLoS One. 2008;3(12):e4098.
106. Creek DJ, et al. Metabolomics-based screening of the malaria box reveals both novel and established mechanisms of action. Antimicrob Agents Chemother. 2016;60(11):6650-63.
107. Pretzel J, et al. Characterization and redox regulation of plasmodium falciparum methionine adenosyltransferase. J Biochem. 2016;160(6):355-67.
108. Salcedo-Sora JE, et al. The molecular basis of folate salvage in plasmodium falciparum characterization of two folate transporters. J Biol Chem. 2011;286(52):44659-68.
109. Wishart DS, et al. HMDB: the human metabolome database. Nucleic Acids Res. 2007;35(suppl 1):D521-6.
110. Wang J, et al. Haem-activated promiscuous targeting of artemisinin in plasmodium falciparum. Nat Commun. 2015;6:10111.
111. Singh S, et al. Characterization of Simian malarial parasite (plasmodium knowlesi)-induced putrescine transport in rhesus monkey erythrocytes a NOVEL PUTRESCINE CONJUGATE ARRESTS IN VITRO GROWTH OF SIMIAN MALARIAL PARASITE (PLASMODIUM KNOWLESI) AND CURES MULTIDRUG RESISTANT MURINE MALARIA (Plasmodium YOELII) INFECTION IN VIVO. J Biol Chem. 1997;272(21):13506-11.
112. Assaraf YG, et al. Effect of polyamine depletion on macromolecular synthesis of the malarial parasite, plasmodium falciparum, cultured in human erythrocytes. Biochem J. 1987;242(1):221-6.
113. Stevens L. The biochemical role of naturally occurring polyamines in nucleic acid synthesis. Biol Rev. 1970;45(1):1-25.
114. Mandal S, et al. Depletion of cellular polyamines, spermidine and spermine, causes a total arrest in translation and growth in mammalian cells. Proc Natl Acad Sci. 2013;110(6):2169-74.
115. Teuscher F, et al. Phenotypic changes in artemisinin-resistant plasmodium falciparum lines in vitro: evidence for decreased sensitivity to dormancy and growth inhibition. Antimicrob Agents Chemother. 2012;56(1):428-31.
116. Srivastava A, et al. Stage-specific changes in plasmodium metabolism required for differentiation and adaptation to different host and vector environments. PLoS Pathog. 2016;12(12):e1006094.
117. Müller S, Kappes B. Vitamin and cofactor biosynthesis pathways in plasmodium and other apicomplexan parasites. Trends Parasitol. 2007;23(3):112-21.
118. Maenpuen S, et al. Characterization of plasmodium falciparum serine hydroxymethyltransferase-a potential antimalarial target. Mol Biochem Parasitol. 2009;168(1):63-73.
119. Salcedo E, Sims PFG, Hyde JE. A glycine-cleavage complex as part of the folate one-carbon metabolism of plasmodium falciparum. Trends Parasitol. 2005;21(9):406-11.
120. Pornthanakasem W, et al. Plasmodium serine hydroxymethyltransferase: indispensability and display of distinct localization. Malar J. 2012;11(1):387.
121. França TCC, Pascutti PG, Ramalho TC. A three-dimensional structure of plasmodium falciparum serine hydroxymethyltransferase in complex with glycine and 5-formyl-tetrahydrofolate. Homology modeling and molecular dynamics. Biophys Chem. 2005;115(1):1-10.
122. Schulz JB, et al. Glutathione, oxidative stress and neurodegeneration. Eur J Biochem. 2000;267(16):4904-11.
123. Mittler R. Oxidative stress, antioxidants and stress tolerance. Trends Plant Sci. 2002;7(9):405-10.
124. Becker K, et al. Oxidative stress in malaria parasite-infected erythrocytes: host-parasite interactions. Int J Parasitol. 2004;34(2):163-89.
125. Färber PM, et al. Molecular cloning and characterization of a putative glutathione reductase gene, the PfGR2 gene, from plasmodium falciparum. Eur J Biochem. 1996;239(3):655-61.
126. Kehr S, et al. Compartmentation of redox metabolism in malaria parasites. PLoS Pathog. 2010;6(12):e1001242.
127. Ritchie, M.E., et al., Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res, 2015. 43(7): p. e47-e47.
128. White LJ, et al. Defining the In Vivo Phenotype of Artemisinin-Resistant Falciparum Malaria: A Modelling Approach. PLoS Med. 2015;12(4):e1001823.
129. Liaw A, Wiener M. Classification and regression by randomForest. R News. 2002;2(3):18-22.
130. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc. Series B (Methodological). 1995:289-300.
131. Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Ann Stat. 2001:1165-88.
132. Becker SA, et al. Quantitative prediction of cellular metabolism with constraint-based models: the COBRA toolbox. Nat Protoc. 2007;2
133. Orth JD, Thiele I, Palsson BO. What is flux balance analysis? Nat Biotech. 2010;28(3):245-8.
134. Oberhardt MA, et al. Metabolic network analysis of Pseudomonas Aeruginosa during chronic cystic fibrosis lung infection. J Bacteriol. 2010;192
135. Gudmundsson S, Thiele I. Computationally efficient flux variability analysis. BMC Bioinform. 2010;11(1):489.
136. Kanehisa M, et al. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 2016;44(D1):D457-62.
137. Gasteiger E, et al. ExPASy: the proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res. 2003;31(13):3784-8.
138. Ginsburg H. Progress in in silico functional genomics: the malaria metabolic pathways database. Trends Parasitol. 2006;22(6):238-40.
139. Yeh E, DeRisi JL. Chemical Rescue of Malaria Parasites Lacking an Apicoplast Defines Organelle Function in Blood-Stage Plasmodium falciparum. PLoS Biol. 2011;9(8):e1001138.
140. Woodrow CJ, Burchmore RJ, Krishna S. Hexose permeation pathways in plasmodium falciparum-infected erythrocytes. Proc Natl Acad Sci U S A. 2000;97(18):9931-6.
141. Anfinsen CB, et al. STUDIES ON MALARIAL PARASITES: VIII. FACTORS AFFECTING THE GROWTH OF PLASMODIUM KNOWLESI IN VITRO. J Exp Med. 1946;84(6):607-21.
142. Jiang L, et al. Potent and selective activity of a combination of thymidine and 1843U89, a folate-based thymidylate synthase inhibitor, against plasmodium falciparum. Antimicrob Agents Chemother. 2000;44(4):1047-50.
143. Yu M, et al. The fatty acid biosynthesis enzyme FabI plays a key role in the development of liver-stage malarial parasites. Cell Host Microbe. 2008;4(6):567-78.
144. Vaughan AM, et al. Type II fatty acid synthesis is essential only for malaria parasite late liver stage development. Cell Microbiol. 2009;11(3):506-20.
145. Deng X, et al. Structural plasticity of malaria dihydroorotate dehydrogenase allows selective binding of diverse chemical scaffolds. J Biol Chem. 2009;284(39):26999-7009.
146. McRobert L, McConkey GA. RNA interference (RNAi) inhibits growth of plasmodium falciparum. Mol Biochem Parasitol. 2002;119(2):273-8.
147. Nguyen, C., et al., Deoxyuridine triphosphate nucleotidohydrolase as a potential antiparasitic drug target. (0022-2623 (Print)).
148. Thornalley, P.J., R.J. Strath M Fau - Wilson, and R.J. Wilson, Antimalarial activity in vitro of the glyoxalase I inhibitor diester, S-p-bromobenzylglutathione diethyl ester. (0006-2952 (Print)).
149. Hanada K, et al. Plasmodium falciparum phospholipase C hydrolyzing sphingomyelin and lysocholinephospholipids is a possible target for malaria chemotherapy. J Exp Med. 2002;195(1):23-34.
150. Silva, A.M., et al., Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum. (0027-8424 (Print)).
151. Hoepfner D, et al. Selective and specific inhibition of the plasmodium falciparum lysyl-tRNA synthetase by the fungal secondary metabolite cladosporin. Cell Host Microbe. 2012;11(6):654-63.
152. Patzewitz EM, Wong EH, Muller S. Dissecting the role of glutathione biosynthesis in plasmodium falciparum. Mol Microbiol. 2012;83(2):304-18.
153. Sturm N, et al. Identification of proteins targeted by the thioredoxin superfamily in plasmodium falciparum. PLoS Pathog. 2009;5(4):e1000383.
154. Belorgey D, Lanfranchi DA, Davioud-Charvet E. 1,4-naphthoquinones and other NADPH-dependent glutathione reductase-catalyzed redox cyclers as antimalarial agents. Curr Pharm Des. 2013;19(14):2512-28.
155. Muller S. Role and regulation of glutathione metabolism in plasmodium falciparum. Mol. 2015;20(6):10511-34.
156. Pastrana-Mena R, et al. Glutathione reductase-null malaria parasites have normal blood stage growth but arrest during development in the mosquito. J Biol Chem. 2010;285(35):27045-56.